Results 61 to 70 of about 24,654 (177)
Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR.
Yuming Wei +2 more
doaj +1 more source
Gramicidin Inhibits Lung Cancer Metastasis by Suppressing the ABL‐MMP9 Signaling Axis
Gramicidin inhibits ABL expression in lung cancer cells, promoting the downregulation of MMP9 expression. Blockade of the ABL–MMP9 signaling axis attenuates the migration and invasion capacity of cancer cells, ultimately suppressing lung metastasis. ABSTRACT Lung cancer, the deadliest malignant tumor worldwide, consists predominantly of non‐small cell ...
Xiuying Li, Ling Chen
wiley +1 more source
Cytoreductive therapy reduces JAK2V617F+ blood velocity and adhesion to activated endothelium
British Journal of Haematology, EarlyView.
Angelica DaSilva +8 more
wiley +1 more source
Protein Lactylation in Cancer: From Mechanisms to Therapy
Increased glycolysis and lactate accumulation promote histone and nonhistone protein lactylation, linking tumor metabolic reprogramming to treatment adaptation. Lactylation enhances DNA repair, suppresses antitumor immunity, strengthens antioxidant defenses, and facilitates cell‐cycle checkpoint escape, collectively promoting resistance to chemotherapy,
Wentian Huang +8 more
wiley +1 more source
An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders
In this work, we describe the advantages of multiplex-PCR in the specific detection of BCR-ABL transcripts in different hematological disorders and its sensitivity compared to nested PCR.
Darío A. Sastre +5 more
doaj +1 more source
Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo +8 more
wiley +1 more source
BACKGROUND AND OBJECTIVES: Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on
S Gatto +12 more
doaj
Philadelphia chromosome-positive (Ph+) leukemia is a fatal hematological malignancy. Although standard treatments with tyrosine kinase inhibitors (TKIs) have achieved remarkable success in prolonging patient survival, intolerance, relapse, and TKI ...
Mengya Zhao +10 more
doaj +1 more source
Background The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome. The p185BCR/ABL or the p210BCR/ABL fusion proteins are encoded as a result
Afsar A. Mian +5 more
doaj +1 more source

